|
Malignant neoplasm of prostate
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
Our data support that the CYP3A5*3 polymorphism may be associated with increased risk of prostate cancer, particularly in African populations.
|
29970707 |
2018 |
|
Malignant neoplasm of prostate
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
The interaction of CYP3A5 polymorphisms along the androgen metabolism pathway in prostate cancer.
|
18306354 |
2008 |
|
Malignant neoplasm of prostate
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
In summary, this meta-analysis suggests that CYP3A4 A392G polymorphism is associated with increased prostate cancer risk among Caucasians and CYP3A5 Met235Thr polymorphism is not associated with the risk of cancer.
|
24989928 |
2014 |
|
Malignant neoplasm of prostate
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
We found no association of CYP3A5 genotypes with prostate cancer or disease severity.
|
15548719 |
2004 |
|
Malignant neoplasm of prostate
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that the CYP3A4 and CYP3A5 variants, or other alleles on the haplotypes they help distinguish, are associated with prostate cancer risk and aggressiveness.
|
14504207 |
2003 |
|
Malignant neoplasm of prostate
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
The CYP3A5 gene polymorphism did not influence significantly a risk of developing of prostate cancer in general.
|
15876487 |
2005 |
|
Prostatic Neoplasms
|
0.330 |
GeneticVariation
|
group |
LHGDN |
Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer.
|
17914095 |
2007 |
|
Prostatic Neoplasms
|
0.330 |
GeneticVariation
|
group |
LHGDN |
The interaction of CYP3A5 polymorphisms along the androgen metabolism pathway in prostate cancer.
|
18306354 |
2008 |
|
Prostatic Neoplasms
|
0.330 |
GeneticVariation
|
group |
LHGDN |
CYP3A5 gene polymorphism and risk of prostate cancer in a Japanese population.
|
15876487 |
2005 |
|
Schizophrenia
|
0.320 |
GeneticVariation
|
disease |
LHGDN |
One polymorphism at DRD2 gene, five at DRD3, 24 at CYP2D6, nine at CYP3A4 gene, and one at CYP3A5 gene were genotyped in a sample of 186 patients with schizophrenia.
|
18551040 |
2008 |
|
Schizophrenia
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
One polymorphism at DRD2 gene, five at DRD3, 24 at CYP2D6, nine at CYP3A4 gene, and one at CYP3A5 gene were genotyped in a sample of 186 patients with schizophrenia.
|
18551040 |
2008 |
|
Kidney Diseases
|
0.310 |
GeneticVariation
|
group |
BEFREE |
To explore the association between CYP3A4 and CYP3A5 gene polymorphisms and blood pressure response to amlodipine among participants from the African-American Study of Kidney Disease and Hypertension Trial randomized to amlodipine (n = 164).
|
19907160 |
2010 |
|
Schizophrenia and related disorders
|
0.310 |
GeneticVariation
|
group |
BEFREE |
In this study we explored possible epistasis between CYP2D6 (*3, *4, *5, *6 and *1xN), CYP3A5 (*3), CYP1A2 (*1C and *1F) and ABCB1 (G2677T) in schizophrenia and related disorders.
|
21142916 |
2010 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer.
|
29115708 |
2018 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Further subgroup analysis by ethnicity indicated that CYP3A5*3 polymorphism was associated with an increased risk of cancer among Asian and Caucasian populations, but not among African populations.
|
23584898 |
2013 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The aim of this study was to document CYP3A5 genotype, vincristine pharmacokinetics (PK) and neurotoxicity profile for 50 children with cancer and determine whether, in a population of Australian children, the CYP3A5 genotype influenced the pharmacodynamics of vincristine as reflected by peripheral neurotoxicity.
|
21658147 |
2011 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In this study, distribution of CYP3A5 alleles among Turkish children with malignancies, relation between CYP3A5 genotype and neurotoxicity rates, as well as severity and duration of neuropathy and total vincristine doses were investigated.
|
28697165 |
2017 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
A total of 127 breast cancer subjects who were premenopausal at cancer diagnosis and underwent cyclophosphamide-based chemotherapy were genotyped for nine single-nucleotide polymorphisms (SNPs) in enzymes involved in cyclophosphamide activation (CYP3A4, CYP2B6, CYP3A5) and detoxification (GSTA1, GSTM1, GSTP1, GSTT1).
|
19376514 |
2010 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In summary, this meta-analysis suggests that CYP3A4 A392G polymorphism is associated with increased prostate cancer risk among Caucasians and CYP3A5 Met235Thr polymorphism is not associated with the risk of cancer.
|
24989928 |
2014 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Screening for wild-type CYP3A5*1 and CYP3A5*3 single nucleotide polymorphism by use of Taqman MGB probe allelic discrimination was performed in 67 patients with cancer (58 Caucasian patients).
|
15179407 |
2004 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Genomic DNA from 108 cancer patients receiving intravenous MDZ and 45 undergoing the erythromycin breath test was analyzed for CYP3A4*22 (rs35599367 C>T) and CYP3A5*3.
|
23327575 |
2013 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
CYP3A5 genotype may affect cancer susceptibility.
|
16430309 |
2006 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We evaluated whether SNPs in the cytochrome P450 3A family (CYP3A4*1B, CYP3A5*3 and CYP3A5*6) were associated with relapse risk on a national Children's Cancer Group (CCG) paediatric ALL trial (CCG-1891).
|
12846892 |
2003 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We conclude that although untreated blood pressure may be higher in blacks with the CYP3A5*3/*3 genotype, the CYP3A5*1 allele may be associated with hypertension that is more refractory to treatment in this ethnic group.
|
15596575 |
2005 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
To explore the association between CYP3A4 and CYP3A5 gene polymorphisms and blood pressure response to amlodipine among participants from the African-American Study of Kidney Disease and Hypertension Trial randomized to amlodipine (n = 164).
|
19907160 |
2010 |